NurExone Biologic has announced results from an independent study indicating that its exosomes outperformed a recognized commercial industry standard in several regenerative functions, including nerve repair, wound healing, immune modulation, and tissue regeneration. According to the company, this analysis highlights the potential of NurExone’s exosomes for both therapeutic and aesthetic applications.
Key findings from the study include:
- Approximately 1.8-fold higher neurological regenerative potential compared to the commercial standard
- Nearly double the anti-inflammatory activity
- Two-fold increase in both tissue-regeneration and wound-healing signals
The analysis, conducted by TAmiRNA, an ISO 13485‑certified molecular diagnostics laboratory, reportedly completed a comprehensive evaluation of the extracellular vesicle (EV) microRNA content of NurExone’s exosomes and compared it to a commercial reference. Bioinformatic analyses indicated that NurExone’s exosomes are enriched with microRNAs supporting key regenerative processes.
Jacob Licht, Chief Executive Officer of ExoTOP Inc. (NurExone’s U.S. subsidiary), stated: “This data confirms that the naïve exosomes that will be manufactured by our U.S. subsidiary, ExoTOP Inc. (“ExoTOP”), will carry a strong regenerative and therapeutic punch. Delivering more than twice the wound-healing signals than the industry benchmark suggests applications in aesthetic skin rejuvenation, wound care and orthopedic tissue repair. As we scale production in the United States with our patent-pending 3D production process, ExoTOP is expected to generate multiple revenue streams and provide high-performance exosomes to partners across regenerative medicine.”
Dr. Tali Kizhner, Director of R&D of NurExone Biologic, added: “Our exosomes carry complex cargo with diverse therapeutic potential, simultaneously being effective in neuroprotection and reduction in inflammation. This combination is especially powerful in the nervous system, where inflammation usually prevents healing. The benchmarking analysis confirms that our exosomes naturally carry a significant amount of the molecular signals needed to create the conditions required for meaningful nerve regeneration.”
NurExone reports that its exosomes are produced from a proprietary master cell bank maintained under rigorously controlled conditions, which is intended to ensure the reproducibility and consistency of exosome production for potential clinical use. The company states that this consistency is essential for clinical translation and future patient applications.
This multi-modal potency profile suggests potential use in therapeutic nerve repair as well as aesthetic and longevity-focused regenerative applications.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
